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Cystic ﬁbrosis (CF) is the most common lethal genetic diseases. It is caused by
mutations in the gene encoding the cystic ﬁbrosis transmembrane conductance
regulator (CFTR), which leads to the deterioration of the lung function. Some
lines of evidence suggest that there is a statistically signiﬁcant difference between
males and females, mostly between 1 to 20 years of age, with an approximate
four-year difference in median survival age. Indeed, survival in females is poorer
than in males but the poorer survival rates in females remain unexplained. We ﬁrst
expose the lines of evidence showing the gender difference regarding the prognosis
of CF. Using the most recent ﬁnding in basic and clinical sciences; deleterious
risk factors are considered as potential explanations. Differences between male
and female regarding Pseudomonas aeruginosa infection, nutritional status, health-
related quality of life, X-linked gene expression, CF modiﬁers, sex hormones and
difference in drug response are exposed with the aim to show that some of these
factors may be involved in the gender difference. Although new treatments tend to
erase the gender difference in CF, this difference exists and the explanatory factors
could help to understand the physiopathology of the disease and could open new
ﬁelds of research.
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Introduction: New indications for ICU admissions arise as the survival rate
increased in CF patients.
Aim: to study the outcome of CF patients admitted to ICU and to identify risk
factors concerning this treatment modality.
Methods: We reviewed the patients’ medical charts characteristics, modality of
intervention, risk factors for death and outcome of all CF patients who admitted
to intensive care unit in our center between 1996–2006. The data is comprised of
two groups. Group-1 (n = 17) suffered from moderate airway obstruction and were
admitted to ICU with life threatening but reversible complications. Group-2 (n = 31)
consisted of patients with acute on chronic respiratory failure.
Results: The duration of ICU was 4.6±3.6 days in group-1 and 10±6days in group-
2. A single patient from group-1 died due to electrolyte imbalance. In group-2 23/31
subjects died during the ICU. Of them 11 died during mechanical ventilation; 6 were
intubated before LTX and 3 who underwent LTX without mechanical ventilation. 7
patients are still alive after LTX were treated for a prolonged period with Bi-level
positive pressure ventilation (BIPAP).
Conclusion: Our study indicates a very poor prognosis in patients who necessitate
MV, either they’re in an acute respiratory failure or during the waiting period
for lung transplantation. End-Stage lung disease can be treated successfully when
possible with BIPAP modality which can serve as a bridge for LTX. Reversible
complications can be managed appropriately in the ICU setting.
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P. aeruginosa forms bioﬁlms in the CF lung which evade host defences &
antibiotics. Bioﬁlm maturation & virulence factor expression are controlled by
quorum sensing molecules. We report the ﬁrst clinical trial in man of a quorum
sensing inhibitor. We randomised 34 patients to garlic capsules 656mg daily or olive
oil 656mg, taken with the evening meal (usual enzyme dose). Clinical outcomes &
safety bloods were measured at baseline & end of treatment. We recorded antibiotic
courses & acceptability. Treatment was for 8 weeks. In this proof of concept study,
analysis was per protocol. Eight patients withdrew, leaving 26 patients for per
protocol analysis (13 garlic). Clinical outcomes are shown in the table. During the
study 7 patients in the garlic group & 5 placebo received IV antibiotics. At the end of
treatment 5 patients in each group had safety bloods (liver function & triglycerides)
above normal & 5 patients in the garlic group (1 placebo) reported minor adverse
effects. Garlic capsules were safe, with only minor adverse effects. There was a
non-signiﬁcant improvement in clinical outcomes which we will investigate in a
larger study.
Supported by: EU (Marie Curie), Boots, University of Nottingham & NHS R&D.
Outcome P
Garlic mean
(SD)
Placebo mean
(SD)
Mean difference (95%CI)
FEV1 (% change from baseline) −2.0 (12.3) −3.6 (11.3) 1.6 (−12.7 to 15.9) 0.8
Wt (% change from baseline) 1.0 (2.0) 0.6 (2.0) 0.4 (−1.3 to 2.0) 0.6
Median (range) Median (range) Median difference (95%CI)
Change in clinical score
(minus = improvement)
−1 (−3 to 5) 1 (−1 to 4) −1 (−3 to 0) 0.16
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Objective: The lung disease of cystic ﬁbrosis (CF) is associated with a chronic
inﬂammatory reaction and an over abundance of oxidants relative to antioxidants.
The aim of this study was to investigate the effect of inhaled steroids on bronchial
hyperreactivity, oxidative status, clinical and inﬂammatory parameters in patients
with CF.
Method: The bronchial hyperreactivity was measured with metacholine challange
test while the oxidative damage intensity was evaluated by measuring plasma
concentrations of malondialdehyde (MDA). Inﬂammatory status was evaluated by
measuring hs-CRP levels and oxidative burst of monocytes. MDA measurements
were done with HPLC and hs-CRP immunoturbidometrically. Respiratory burst
of monocytes were measured by luminol-enhanced chemiluminescence before and
after phorbol-myristate acetate (PMA) induction.
Results: Twenty-nine CF cases (69% female, mean age: 10.5 years) who were
not receiving any form of steroids at least for two months were enrolled. Seventeen
patients received 2mg/day nebulised budesonide and 12 patients received nebulised
serum physiologic after randomisation. Plasma concentrations of MDA, total white
blood cell count and percentage of neutrophiles in the sputum decreased signiﬁ-
cantly after treatment with budesonide but there was no difference between the two
groups in terms of bronchial hyperreactivity, clinical and inﬂammatory parameters.
Conclusions: Nebulised budesonide was not found to be effective for treatment in
patients with CF in terms of bronchial hyperreactivity, clinical and inﬂammatory
parameters.
